NovoCure Limited (NVCR)
After hours:
| Previous Close | 14.19 |
| Open | 14.53 |
| Bid | 14.71 x 400 |
| Ask | 14.79 x 200 |
| Day's Range | 14.31 - 15.42 |
| 52 Week Range | 10.87 - 83.60 |
| Volume | |
| Avg. Volume | 1,294,580 |
| Market Cap | 1.59B |
| Beta (5Y Monthly) | 0.43 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
Novocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon
ROOT, Switzerland, May 02, 2024--Novocure (NASDAQ: NVCR) announced today that it has entered into a new five-year up to $400 million committed senior secured credit facility with funds managed by Pharmakon Advisors, LP. The committed capital will be available to Novocure in four tranches of $100 million. The first $100 million was issued at closing, and the second $100 million will be issued by June 30, 2025. An additional $200 million is available to be drawn across two tranches, at Novocure’s
- Business Wire
Novocure Reports First Quarter 2024 Financial Results
ROOT, Switzerland, May 02, 2024--Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended March 31, 2024. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields).
- Business Wire
Results of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024
ROOT, Switzerland, April 24, 2024--Novocure (NASDAQ: NVCR) today announced the results of the METIS phase 3 clinical trial in brain metastases from non-small cell lung cancer (NSCLC) will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, to be held from May 31 to June 4.
